Our study suggests high pretreatment albumin levels, low pretreatment MIP-1β levels, non-liver metastasis, low Treg density and different gene expression in the tumor microenvironment may be potential predictive biomarkers of nivolumab plus regorafenib in refractory pMMR colorectal cancer. Here, ALB is linked to colorectal cancer.